Acenxion Biosytems
Lawrence, US · Founded 2020 · Delaware corporation
Founders & leadership
BS
Brian StruchtemeyerExecutive
RS
Roy SwigerExecutive
Board
HG
Howard GoldsteinBoard director
WC
Wayne CarterBoard director
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 2 rounds · 2023–2024
▶$1.1MraisedAug 2024 · 5 investors · BiotechnologyRule 506(b)
▶$1.1MraisedAug 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Howard GoldsteinDirector
- Brian StruchtemeyerExecutive Officer, Director
- Roy SwigerExecutive Officer, Director
- Wayne CarterDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50KraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian StruchtemeyerDirector
- Howard GoldsteinDirector
- Wayne CarterDirector
- Roy SwigerExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $50K
- Minimum investment
- $50K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Acenxion Biosytems raised?
- Acenxion Biosytems has disclosed $1.1M raised across 2 rounds.
- Where is Acenxion Biosytems headquartered?
- Acenxion Biosytems is headquartered in Lawrence, US.